8446 related articles for article (PubMed ID: 2305835)
1. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
O'Hara CJ; Corson JM; Pinkus GS; Stahel RA
Am J Pathol; 1990 Feb; 136(2):421-8. PubMed ID: 2305835
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
Delahaye M; Hoogsteden HC; Van der Kwast TH
J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
[TBL] [Abstract][Full Text] [Related]
3. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
[TBL] [Abstract][Full Text] [Related]
4. Differential diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies against gastrointestinal carcinoma antigen and stage-specific embryonic antigen.
Ernst CS; Atkinson B; Chianese D; Peters J; Perry M; Herlyn M; Koprowski H
Appl Pathol; 1986; 4(3):115-24. PubMed ID: 2885017
[TBL] [Abstract][Full Text] [Related]
5. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
6. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
Zhu W; Michael CW
Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
[TBL] [Abstract][Full Text] [Related]
7. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas.
Ramaekers F; van Niekerk C; Poels L; Schaafsma E; Huijsmans A; Robben H; Schaart G; Vooijs P
Am J Pathol; 1990 Mar; 136(3):641-55. PubMed ID: 1690512
[TBL] [Abstract][Full Text] [Related]
8. Distinctive microvillous brush border staining with HBME-1 distinguishes pleural mesotheliomas from pulmonary adenocarcinomas.
Dahlstrom JE; Maxwell LE; Brodie N; Zardawi IM; Jain S
Pathology; 2001 Aug; 33(3):287-91. PubMed ID: 11523926
[TBL] [Abstract][Full Text] [Related]
9. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
10. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
[TBL] [Abstract][Full Text] [Related]
11. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
12. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
13. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
14. Malignant mesothelioma: ultrastructural distinction from adenocarcinoma.
Warhol MJ; Hickey WF; Corson JM
Am J Surg Pathol; 1982 Jun; 6(4):307-14. PubMed ID: 6287872
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma.
Stahel RA; O'Hara CJ; Waibel R; Martin A
Int J Cancer; 1988 Feb; 41(2):218-23. PubMed ID: 3276635
[TBL] [Abstract][Full Text] [Related]
16. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
Müller AM; Franke FE; Müller KM
Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
[TBL] [Abstract][Full Text] [Related]
17. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
Ordóñez NG
Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions. Comparison with intermediate filament distribution by electron microscopy.
Kahn HJ; Hanna W; Yeger H; Baumal R
Am J Pathol; 1982 Nov; 109(2):206-14. PubMed ID: 6182803
[TBL] [Abstract][Full Text] [Related]
19. Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions.
Szpak CA; Johnston WW; Lottich SC; Kufe D; Thor A; Schlom J
Acta Cytol; 1984; 28(4):356-67. PubMed ID: 6205527
[TBL] [Abstract][Full Text] [Related]
20. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
Corson JM; Pinkus GS
Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
